Due to the significant similarity between the kinase domains of ROS1 and ALK, the NCCN guidelines approved ALK inhibitors ceritinib [163], crizotinib [164], entrectinib [165], and lorlatinib [166] for treating NSCLC with ROS1 rearrangement. This evidence concerns the gene ALK and non-small cell lung carcinoma.